Attendee search 

Lumira Capital is a Venture Capital firm that changed its name from MDS Capital In 2007 and have been investing in companies since 1989. The firm is based in Toronto will additional offices in Boston and Montreal. The firm currently manages 2 funds for a total of approximately $180 million in assets under management. The firm’s Lumira Capital II fund currently hold approximately $115 million in assets and is looking to invest in companies across North America. The firms Merck Lumira Biosciences fund formed via a partnership with Merck Serano, currently holds around $65 million in assets and is looking for early stage opportunities in companies located in or looking to move to Quebec. The firm typically makes initial investments ranging from $2-$5 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm plans to make 4-6 investments over the next 6-9 months.

River Cities Capital Fund is a private equity firm founded in 1994 and based in Cincinnati, Ohio. The firm manages approximately $500 million under management and is currently investing out of its 2014 vintage $200 fund. The firm looks to make investments of $5-$15 million initially up to $20 million over the investments lifetime. The firm is willing to invest throughout the United States and is looking to make approximately 4-6 equity investments over the next 6 to 9 months.

For more than 35 years STRATEC Biomedical AG is a business partner for the development and manufacture of fully automated analyzer systems. It's headquarter is located in Birkenfeld, Germany and it has nearly 500 employees in 5 locations worldwide. The public owned company has cooperations with 15 of the 20 IVD companies worldwide and has boosted its annual sales from USD 10.4 million in 1998 (IPO) to USD 122.4 million in 2014. STRATEC has strived to achieve market-leading expertise and to build a technology pool that is unique to its industry. The company invests in a variety of fields within the diagnostic and life science sector including medical devices.

Sathguru Management Consultants is a niche emerging markets focused strategy and innovation advisory firm.  Founded in 1985 in India, Sathguru’s expertise includes South Asia focused corporate strategy, M&A and innovation advisory encompassing international innovation access, advancement and commercialization.  Sathguru has a team of around 150 professionals across service offerings and has offices in India and USA. 

Plug and Play Ventures (a successor fund to Amidzad Partners) is a private/family investment vehicle based in Silicon Valley, CA. The fund is a structured organization for making angel investments in pre-seed or seed rounds. Investments are in the form of equity; in the next 6 months Plug and Play Ventures expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector. Plug and Play also provides a three-month accelerator program. The firm will consider investing in companies worldwide.

Plug and Play Ventures is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component. Healthcare IT, biosensors, wearables and health monitoring devices are of interest. While the firm is open to investing in any indication, Plug and Play is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders. In the healthcare IT sector, Plug and Play Ventures is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic, or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.

F. Hoffmann-La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche is looking for first-in-class or best-in-class opportunities that address diseases of unmet medical need and have the potential to revolutionize the standard of care. Roche focuses on their main disease therapy areas – oncology and Immuno-oncology, ophthalmology, infectious diseases and neurosciences–as well as looking at opportunities in promising technologies and early-stage collaborations. Beyond the asset, Roche always look for the right partnership and cultural fit. Roche also seeks collaboration in diagnostics, specifically biomarkers.